A recent genome-wide association study of IgA nephropathy (IgAN) identified 1q32, which contains multiple complement regulatory genes, including the complement factor H (CFH) gene and the complement factor H-related (CFHRs) genes, as an IgAN susceptibility locus. Abnormal complement activation caused by a mutation in CFHR5 was shown to cause CFHR5 nephropathy, which shares many characteristics with IgAN. To explore the genetic effect of variants in CFHR5 on IgAN susceptibility, we recruited 500 patients with IgAN and 576 healthy controls for genetic analysis. We sequenced all exons and their intronic flanking regions as well as the untranslated regions of CFHR5 and compared the frequencies of identified variants using the sequence kernel association test. We identified 32 variants in CFHR5, including 28 rare and four common variants.
IgA nephropathy (IgAN) is the most common primary GN worldwide. 1 Recently, important discoveries have been made regarding the pathogenesis of IgAN, [2] [3] [4] [5] such as the aberrant glycosylation of IgA1 and the presence of antiglycan antibodies in circulation as well as the role of transferrin receptors in glomeruli. However, there are still many unknown aspects in IgAN. Although complement activation has been widely accepted for a long time to occur in IgAN, 6 the exact pathways and regulatory mechanisms are still unclear.
Meanwhile, from racial and ethnic variations in disease incidence to familial aggregation of IgAN, increasing evidence implied a genetic effect on IgAN. A recent genome-wide association study (GWAS) 7 and a GWAS replication study 8 identified and confirmed 1q32 as an IgAN susceptibility locus, which suggested the involvement of genetic abnormalities in the complement factor H (CFH) and/or the complement factor H-related (CFHRs) genes in IgAN. This region contains several complement regulatory genes, CFH-CFHRs. CFHRs, which include CFHR3, CFHR1, CFHR4, CFHR2, and CFHR5, share high sequence homology with CFH. Accordingly, they have similar structures, which are built on a motif of distinct functional domains called short consensus repeats (SCRs), and similar functions in complement regulation, 9 although their precise biologic roles are not completely identical.
Recently, a novel disease named CFHR5 nephropathy was identified after genetic analysis of a pedigree of Cypriot ancestry with primary GN. 10 Patients with CFHR5 nephropathy presented with many characteristics, including young age onset, tendency in men, repeated episodes of synpharyngitic hematuria, mesangial matrix expansion, increased glomerular cellularity, glomerular staining for C3, mesangial electrondense deposits, and high recurrence rate after renal transplantation, which shared many similarities with IgAN. 11 Patients with CFHR5 nephropathy bear the same heterozygous internal duplication of the CFHR5 gene, which is likely to be the cause of their glomerular lesions.
The CFHR5 gene is located at 1q31.3 and spans 42 kb of the human genome. Its encoded product is a 62-kD protein named CFHR5. The CFHR5 gene has 10 exons encoded in nine SCRs, in which SCR3-7 and SCR8-9 showed a high homology with SCR10-14 and SCR19-20 in CFH, respectively. CFHR5 is the most recently discovered CFHR protein, and it is also the one that showed the most similarity with CFH among the five CFHRs. 12 As with CFH and other CFHRs, CFHR5 is produced in the liver, circulates in plasma, and functions as a complement regulatory protein. Until today, the precise mechanism for CFHR5 in complement regulation is still unknown. 13 However, with respect to IgAN, the disease presents complement activation in glomeruli and has clinical features similar to CFHR5 nephropathy, but whether some patients with IgAN have genetic changes in the CFHR5 gene and whether these variants contribute to IgAN susceptibility are still unknown. In this study, using a large population of patients with IgAN, we performed an intensive genetic analysis to explore the genetic effect of variants in the CFHR5 gene on IgAN susceptibility.
RESULTS
Baseline Clinical, Laboratory, and Pathologic Characteristics In total, 1076 individuals were recruited, including 500 patients with IgAN (258 men and 242 women) and 576 healthy controls (310 men and 266 women). The average ages for patients with IgAN and controls were 34.23611.09 and 33.5067.66 years old, respectively. For patients with IgAN, detailed clinical, laboratory, and pathologic characteristics were also available. 33 .20%, and 12.20% of patients, respectively. All patients were regularly followed for at least 1 year, with a mean follow-up time of 56.26 months. Patients' treatment and follow-up were conducted at an IgAN-specific clinic in Peking University First Hospital and consistent with the Kidney Disease Improving Global Outcomes guideline. 14 During follow-up, 16 .80% (84 patients) of these patients reached a composited end point (ESRD, 50% eGFR decline, or death). The clinical, laboratory, and pathologic characteristics of the recruited patients were similar to those of previously reported IgAN cohorts. 15 Identification of Genetic Variants in CFHR5 All exons in the CFHR5 gene were amplified and screened for genetic variants in recruited individuals. In total, 32 variants were identified ( Figure 1 , Table 1 ), including 10 in exons, 18 in introns, two in promoter, and two in 39 untranslated region (UTR). Of 10 exonic variants, eight were nonsynonymous coding (including one nonsynonymous stop gain and nonsynonymous stop loss), and two were synonymous changes. Among 32 variants, 16 were found in the dbSNP database, whereas the other 16 variants were novel. were identified only in patients with IgAN (who exhibited a total of 22 rare variants), nine were identified only in healthy controls (with a total of 23 rare variants), and the other five variants were identified in both patients (23 total rare variants) and controls (21 total rare variants). Because analysis of rare variants requires statistical methods that are fundamentally different than testing common variants, we applied Sequence Kernel Association Test (SKAT), which can evaluate not only rare variants' effect but also, the cumulative effect of rare and common variants. The results of SKAT showed that the combined effect of rare and common variants in CFHR5 had a significant association with IgAN (P=0.03) ( Table 2) . Furthermore, we investigated common and rare variants separately. Rare variants in CFHR5 presented a significant association with IgAN (P=0.002) ( Table 2 ), but common variants did not (P=0.92) ( Table 2) .
Regarding the four common variants, we also performed single variant-level analysis. In accordance with the results from SKAT, no significant difference was observed regarding the allele or genotype frequencies of each single common variant (Table 3) . According to these rare variants in CFHR5, patients with IgAN were divided into two groups: those with rare variants in CFHR5 (43 patients) and those without (457 patients). However, clinical and pathologic manifestations showed no significant differences between the two groups ( Table 4 ). For long-term renal survival, no significant difference was observed between patients in the two groups ( Figure 2 ).
In Silico Functional Prediction of Rare Variants in CFHR5
Because rare variants in CFHR5 showed significant association with IgAN, we next explored their effect on CFHR5 expression, structure, and function. Several types of software were used according to the position of the variants. In total, nine of 28 rare variants were predicted to influence function or expression of CFHR5 ( Figure 3 , Table 5 ). Of these nine, five variants might result in potential pathogenic amino acid changes, including c.332A.C/p. Gln111Pro (identified in patients and controls) in exon 3, c.508G.A/p.Val170Met (identified in patients and controls) and c.533A.G/p.Asn178Ser (identified in patients) in exon 4, c.822A.T/p.Glu274Asp (identified in patients) in exon 6, and c.1357C.T/p.Pro453Ser (identified in controls) in exon 9. Three variants would lead to protein length change, and they included c.776T.A/p.Leu259Termination (identified in patients), a stop-gain variant that produced a shortened CFHR5 protein (258 amino acids only); c.1708T.C/p.Termination570Arg (identified in patients and controls), a stop-loss variant that added 37 amino acids to the C terminus of the wild-type CFHR5 protein; and c.790+2T.C (identified in patients), a variant located 2 bp away from an exon-intron boundary (exon 5 to intron 5) that, thus, appeared to break the GT-AG splicing rule; c.790+2T.C was also predicted to be a splicing site change by the Alternative Splice Site Predictor (ASSP) and software available from the Berkeley Drosophila Genome Project (BDGP). Moreover, c.1710*168G.T (identified in patients) in the 39 UTR, located 168 bp away from the stop codon, was in the microRNA binding region. Therefore, TargetScanHuman 6.2 was used to see Figure 1 . Flowchart of the genetic analysis of CFHR5 variants in IgAN. After screening for variants in CFHR5 in 500 patients with IgAN and 576 healthy controls, 32 variants were identified. After checking against the dbSNP database, 1000 Genome data, and ExAC data to see whether these variants were reported before, 32 variants in CFHR5 were divided into two groups, common variants and rare variants, on the basis of the MAF in controls (cutoff =0.01). Then, variant distribution between patients with IgAN and controls was compared in each group using the SKAT. After the identification of rare variants in CFHR5 associated with IgAN, the functional meaning of these rare variants was predicted by in silico programs. At last, nine potential functional variants were identified, which were located in different SCRs of the CFHR5 protein. CHB, Chinese Han Beijing; dbSNP, single nucleotide polymorphism database; ExAC, exome aggregation consortium; HSF, human splicing finder; SIFT, sorting intolerant from tolerant. whether the variant would interfere with microRNA binding efficiency. The results showed that c.1710*168G.Tmight also be predicted as damaging for its potential influence on the binding of hsa-miR-2117 and hsa-miR-4273 to CFHR5 mRNA.
Detection of C3b Binding Capacity
Within nine rare variants predicted to influence CFHR5 function, seven were nonsynonymous. Comparing these seven nonsynonymous variants between patients and controls, we found four variants that were located in SCR3-5 (c.508G.A/p. Val170Met, c.533A.G/p.Asn178Ser, c.776T.A/p.Leu259-Termination, and c.822A.T/p.Glu274Asp) and showed higher frequencies in IgAN. Because SCR3-5 in CFHR5 had high amino acid identities similar to SCR10-12 in CFH and because SCR12 in CFH has the ability to bind to C3b, 16 we further evaluated their influence on the recombinant CFHR5 proteins (Supplemental Figure 1 ) and its C3b binding capacity. We found that, when 1-4 mg/ml C3b was added, 1 mg/ml CFHR5 protein (including all of our detected allotypes) was within the linearity range for the C3b binding capacity (Supplemental 
DISCUSSION
On the basis of the GWAS identification of CFH-CFHRs as factors associated with IgAN predisposition, 7,17 the high similarity of IgAN with CFHR5 nephropathy, and the evidence of complement activation in IgAN, we suspected that variants in the CFHR5 gene might also play some part in influencing genetic predisposition to the complex disease IgAN. In this study, through genetic analysis of the CFHR5 gene, we found significant genetic association of rare variants in CFHR5 with IgAN, and we further proved an impaired C3b binding capacity of some rare variants in CFHR5.
In recent years, increasing evidence indicated that the allelic spectrum of disease-associated variants at a given locus might include novel, rare, and common variants. Reports from inflammatory bowel disease and rheumatoid arthritis supported the involvement of both rare and common variants from single genes or gene sets in common complex diseases. 18, 19 Recently, after the identification of membranous nephropathy (MN) -associated common variants in PLA2R1 by the GWAS, Coenen et al. 20 convincingly excluded the possibility that rare variants in PLA2R1 are involved in MN pathogenesis. 21 However, for IgAN, although the GWAS identified several diseaseassociated loci and common variants, 7, 17, 22, 23 few studies have focused on rare variants in candidate genes. Here, after screening for variants in the exons, intronic flanking regions, and UTRs of CFHR5, we applied a popular rare variant association test, SKAT, to evaluate the association between variants in CFHR5 and IgAN. 24 SKAT has two distinguishing features among group-wise association tests. First, SKAT can evaluate not only the effect of rare variants but also, the cumulative effect of rare and common variants. 25 Second, SKAT allows for rare variants to have opposite effects (both effective and deleterious) on the traits. 26 Because we identified both rare and common variants as well as their gain-of-function or loss-offunction properties, we tested the genetic associations between IgAN and rare plus common variants, rare variants alone, and common variants alone in CFHR5 by SKAT. Different from the findings in MN, we found that it was rare variants and not common variants in CFHR5 that contribute to IgAN susceptibility. In this study, the proportion of patients with IgAN bearing rare variants in CFHR5 reached 8.6% (43 of 500). Because IgAN is widely regarded as a polygenic disease, rare variants in the CFHR5 gene are likely to play some role in IgAN predisposition, but they are not, as in CFHR5 nephropathy, likely to be the only causal factor in the disease. Accordingly, we failed to observe significant differences regarding clinical findings, pathologic features, and renal outcomes between patients with or without rare variants in CFHR5. In monogenic diseases induced by abnormal complement activation, including aHUS and DDD, mutations in both CFH and CFHR5 were reported, [27] [28] [29] [30] but in complement-involved complex disease, such as SLE, age-related macular degeneration, and IgAN, although variants in CFH were widely investigated, 15, 31, 32 limited studies focused on the CFHR5 gene. To the best of our knowledge, our study is the first to report the association of rare variants in CFHR5 with IgAN. The role of rare variants in CFHR5 still remains to be elucidated in other complementinvolved complex diseases and validated in larger IgAN cohorts of other ethnicities.
By in silico prediction, we identified nine potential functional variants of 28 rare variants to influence the CFHR5 effect, although we cannot exclude the possibility of some others also having functional meaning. Except for c.1710*168G.T, which is located in 39 UTR and predicted to change CFHR5 expression, the other eight variants were assumed to influence CFHR5 function. SCRs are the basic functional domains in CFH and CFHRs, including CFHR5. 12 When we compared the allele frequencies of the eight potential functional variants in patients with IgAN and healthy controls, the interesting thing that we found was that variants that showed higher frequencies in IgAN (c.508G.A, c.533A.G, c.776T.A, c.790+2T.C, and c.822A.T) clustered in SCR3-5, whereas those with higher frequencies in controls (c.1357C.T and c.1708T.C) clustered in SCR8-9.
The variant with comparable frequency between patients and controls (c.332A.C) was located in SCR2. In the SCR3-5 region, we identified five potential pathogenic variants, with higher frequencies in IgAN. Variant c.790
+2T.C is a splicing acceptor site variant. The minor allele C would affect the complex dynamics of splicing and can potentially lead to a functional change of CFHR5 because of erroneous exon skipping or the inclusion of a nonintronic sequence. For the other four variants in SCR3-5, we detected their influence on the CFHR5 protein with regard to C3b binding. Results showed that three variant-associated CFHR5 proteins, CFHR5-M (c.508G.A/p.Val170Met), CFHR5-S (c.533A.G/p.Asn178Ser), and CFHR5-D (c.822A.T/p.Glu274Asp), enhanced the binding of CFHR5 to C3b. Recently, CFHR5 was reported to deregulate complement activation by competing with CFH. 33, 34 Because a high degree of complement activation was associated with poor renal survival in IgAN, it is reasonable for us to suspect CFHR5-M, CFHR5-S, and CFHR5-D as gain of function for CFHR5; therefore, they exhibited stronger competition with CFH, resulted in a higher degree of complement activation, and contributed to IgAN susceptibility. Different from these, CFHR5-Short resulted from a stop-gain variant (c.776T.A/ p.Leu259Termination) and exhibited significantly lower C3b binding capacity. This mutant CFHR5 (CFHR5-Short), as a half-truncated protein (258 amino acids only compared with 569 amino acids in wild-type CFHR5), was prematurely terminated at SCR4, and it, therefore, is missing SCR5-9 and part of SCR4. Because the accurate mechanism for SCR5-9 is still unknown, we suspected that it might change the biologic function of CFHR5 through some other mechanism harbored by SCR5-9, which overcame its influence on C3b binding capacity and contributed to IgAN susceptibility. Unfortunately, our study was unable to clarify the pathogenic mechanism of CFHR5-Short, and therefore, additional studies will be required in the future after the biologic effect of SCR5-9 is revealed.
The other two potential functional variants, which showed higher frequencies in controls, were located in SCR8-9 in CFHR5 and correspond to SCR19-20 in CFH. 12 SCR19-20 in CFH is critical for binding to the cell surface. Most genetic mutations in CFH that induced aHUS, 35 a disease with severe endothelial injury, are located in SCR19-20. 36 Therefore, we assumed that variants in CFHR5 SCR8-9 would have a similar influence and might be associated with endothelial injury. Although we now have considerable evidence regarding endothelial injury in IgAN, [37] [38] [39] the underlying mechanism is still unknown. Additional functional studies are required to clarify whether our identified variants in SCR8-9 of CFHR5 influence its binding to endothelial cells and what their genetic mechanisms are in IgAN. Different from those variants that influenced CFHR5 function, c.1710*168G.T, located in the 39 UTR, was predicted to influence the expression rather than the sequence of CFHR5. In recent years, Figure 2 . Kaplan-Meier renal survival curves of patients with IgAN according to whether patients were with or without rare variants in CFHR5. In our population of patients with IgAN, eventfree survival of composite outcomes was comparable between patients with rare variants in CFHR5 (n=43) and those without rare variants (n=457; P value for log-rank test was P=0.92). increasing microRNA-associated single-nucleotide polymorphisms were found on microRNA target sites within the 39 UTRs of mRNAs, such as hsa-miR-1207-5p in CFHR5 nephropathy, 40 miR-148b in IgAN, 41 and so on. The c.1710*168G.T variant in CFHR5 was at the target site for hsa-miR-2117/hasmiR-4273 binding. The mutant Tallele substituted for the G allele theoretically influences the binding of miR-2117/miR-4273 and therefore, would change CFHR5 levels. It was reported that CFHR5 colocalized with complement-containing glomerular immune deposits in a variety of glomerular pathologic states. 42 Although it has an unclear biologic role, CFHR5 is postulated to have a physiologic role in complement processing within the kidney. We speculated that c.1710*168G.T might contribute to IgAN predisposition through its post-transcriptional regulation of CFHR5 expression. Our study had several limitations. First, we identified several potential functional rare variants. However, C3b binding capacity was only detected in some of them. Additional functional studies are required to reveal their exact biologic roles in IgAN. Second, because we failed to harvest the secreted CFHR5 from an insect cell system, an Escherichia coli system, which lacks post-translational modifications, was used for recombinant CFHR5 protein expression. Whether posttranslational modification would influence the C3b binding capacity of CFHR5 is still unknown. Third, diverse incidences of IgAN were reported in different racial and ethnic populations, and therefore, future replication studies are important to validate the genetic association of CFHR5 in IgAN. We failed to find any genotype-phenotype correlation for rare variants in CFHR5. Whether rare variants in CFHR5 contributed to clinical or pathologic phenotypes or the progression of IgAN is a question awaiting further convincing evidence.
In conclusion, through screening the genetic variants in CFHR5, we found that rare variants in CFHR5 contributed to genetic susceptibility to IgAN, which suggested that CFHR5 is an IgAN susceptibility gene.
CONCISE METHODS

Study Population
Here, we recruited 1076 northern Chinese individuals, including 500 patients with sporadic IgAN (diagnosed from 2003 to 2009) and 576 age-, sex-, and geographically matched unrelated healthy controls during this time interval. The diagnosis of IgAN was proven by renal biopsy on the basis of granular deposition of IgA in the glomerular mesangium by immunofluorescence detection and the deposition of electron-dense material in the mesangium by ultrastructural examination. Patients with Henoch-Schonlein purpura, SLE, and chronic hepatic diseases were excluded by detailed clinical and laboratory examinations.
The study protocol was approved by the Medical Ethics Committee of Peking University, and informed written consent was obtained from all patients. Figure 1 shows the flow chart of genetic analysis applied in our study. 
Association Analyses of Variants in CFHR5 with IgAN
To evaluate the genetic contribution of variants in CFHR5 to IgAN susceptibility, a popular genetic association test, SKAT, was applied. The R package SKAT 1.0.7 was used for the analysis. At first, the combined effect of all variants in CFHR5 was analyzed. Then, variants in CFHR5 were grossly divided into common and rare variants according to their MAF in healthy controls (cutoff =1%). The effects of rare variants alone and common variants alone were evaluated by SKAT_CommonRare. Additionally, for common variants in CFHR5, comparisons of allele and genotype frequencies at the single-variant level were also performed between 500 patients with IgAN and 576 healthy controls.
Comparative Analyses between Patients with IgAN According to Rare Variants in CFHR5
For the enrolled 500 patients with sporadic IgAN, clinical parameters at the time of renal biopsy, including serum IgA level, serum C3 level, serum creatinine level, 24-hour urine protein excretion, and history of hypertension, were collected from the medical records. The eGFR was calculated using the Modified Glomerular Filtration Rate Estimating Equation for Chinese. 44 The Haas classification was assessed in patients whose renal biopsy tissues contained more than eight glomeruli. 45 According to the presence or absence of rare variants in CFHR5, patients with IgAN were divided into two groups: those with rare variants and those without rare variants. At first, baseline clinical manifestations and histologic classifications were compared between the two groups. Then, survival analysis was used to evaluate whether patients in the two groups had a significant difference in long-term renal outcomes. A composite end point, which was defined as 50% eGFR decline, ESRD, or death, whichever occurred first, was used in this study. ESRD was defined as eGFR,15 ml/min per 1.73 m 2 or the need for RRT (such as hemodialysis, peritoneal dialysis, or renal transplantation) for the purpose of this study.
Computational Assessment of Rare Variants in CFHR5
A functional evaluation of the identified rare variants in CFHR5 was analyzed using several in silico prediction programs according to their position in the genome. For variants in the promoter and 59 UTR, promoter 2.0 (http://www.cbs.dtu.dk/services/Promoter/) was used to predict whether the variants were in transcription element binding sites; for those in the coding region, their potential pathogenicity was analyzed by two independent programs: one was Sorting Intolerant from Tolerant (http://sift.jcvi.org/), with prediction that is on the basis of the degree of the conservation of amino acid residues in sequence alignments derived from closely related sequences, and the other was Polymorphism Phenotyping v2 (http://genetics.bwh. harvard.edu/pph2/), in which variants with scores of .2.0, 1.5-2.0, and ,1.5 were defined as probably damaging, possibly damaging, and benign, respectively. For variants in intronic flanking region, splice donor sites or acceptor sites were checked by the splice site prediction software available by the BDGP and the ASSP, which is a sequence analysis tool for the prediction and classification of splice sites. Meanwhile, splicing branch point A was predicted by Human Splicing Finder software (version 2.4.1; http://www.umd.be/HSF/), which helps with the study of the pre-mRNA splicing; for variants in 39 UTR, a microRNA target prediction tool TargetScanHuman 6.2 (http://www.targetscan.org/), which predicts biologic targets of microRNAs by searching for the presence of conserved 8mer and 7mer sites that match the seed region of each microRNA, was used to evaluate their influence on microRNA binding. were supplied by GenScript Corporation through customization. In brief, codon-optimized DNA sequences coding for CFHR5 as well as eight His amino acids at the C terminus of CFHR5, were synthesized and ligated into a pUC57 vector and expressed in E. coli expression systems. Recombinant CFHR5 proteins were purified by His tag affinity chromatography from the culture medium of E. coli. For the detection of the binding capacity of recombinant CFHR5 proteins to C3b, recombinant CFHR5 (1 mg/ml) was coated onto MaxiSorp Plastic Plates (Nalge-Nunc, Rochester, NY) at 4°C overnight. After being blocked with 1% BSA (Sigma-Aldrich, St. Louis, MO), 2 mg/ml C3b (Calbiochem, San Diego, CA) was added, and the mixture was incubated for 1 hour at 37°C. The binding of C3b to CFHR5 was examined by Polyclonal Rabbit Anti-Human C3c Antibody (DAKO, Copenhagen, Denmark) and followed by horseradish peroxidase-labeled donkey anti-rabbit IgG (Santa Cruz Biotechnology, Santa Cruz, CA). The reaction was developed using 3,39,5,59-Tetramethylbenzidine Horseradish Peroxidase Color Development Solution for ELISA (Sigma-Aldrich) and stopped with 1 mol/L sulfuric acid before the absorbance was measured at 450/570 nm. Meanwhile, 0.125 mg/ml recombinant CFHR5 was also coated and blocked as described above, and polyclonal anti-CFHR5 antibody (ab175254; Abcam, Inc., Cambridge, MA) and horseradish peroxidase-labeled goat anti-rabbit IgG (Santa Cruz Biotechnology) were sequentially added and incubated for 1 hour at 37°C. After reaction development and stopping with 1 mol/L sulfuric acid, the absorbance was measured at 450/570 nm.
Statistical Analyses
Statistical analyses were performed using SPSS software (version 16.0; SPSS Inc., Chicago, IL). Normally distributed quantitative variables were expressed as the means6SDs, whereas for those with a nonnormal distribution, the medians and interquartile ranges were used. Categorical data were summarized as absolute frequencies and percentages. For continuous variables, the independent samples t test was used if the data had a normal distribution, and if not, the MannWhitney or Kruskal-Wallis test was performed. Categorical variables were compared using the chi-squared test. Cumulative kidney survival curves were derived using the Kaplan-Meier method, and differences between the curves were analyzed using the log-rank test. A two-tailed P,0.05 was considered statistically significant.
